- Home
- ACHC vs LEGN Comparison
ACHC vs LEGN Comparison
Compare ACHC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHC
- LEGN
- Stock Information
- Founded
- ACHC 2005
- LEGN 2014
- Country
- ACHC United States
- LEGN United States
- Employees
- ACHC N/A
- LEGN N/A
- Industry
- ACHC Medical Specialities
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ACHC Health Care
- LEGN Health Care
- Exchange
- ACHC Nasdaq
- LEGN Nasdaq
- Market Cap
- ACHC 2.1B
- LEGN 7.0B
- IPO Year
- ACHC N/A
- LEGN 2020
- Fundamental
- Price
- ACHC $25.64
- LEGN $27.69
- Analyst Decision
- ACHC Strong Buy
- LEGN Strong Buy
- Analyst Count
- ACHC 10
- LEGN 13
- Target Price
- ACHC $52.25
- LEGN $75.67
- AVG Volume (30 Days)
- ACHC 3.4M
- LEGN 1.5M
- Earning Date
- ACHC 05-12-2025
- LEGN 05-13-2025
- Dividend Yield
- ACHC N/A
- LEGN N/A
- EPS Growth
- ACHC N/A
- LEGN N/A
- EPS
- ACHC 2.04
- LEGN N/A
- Revenue
- ACHC $3,156,417,000.00
- LEGN $728,303,000.00
- Revenue This Year
- ACHC $7.90
- LEGN $65.96
- Revenue Next Year
- ACHC $8.58
- LEGN $52.55
- P/E Ratio
- ACHC $12.53
- LEGN N/A
- Revenue Growth
- ACHC 5.48
- LEGN 112.46
- 52 Week Low
- ACHC $20.36
- LEGN $29.27
- 52 Week High
- ACHC $82.41
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- ACHC 52.63
- LEGN 29.04
- Support Level
- ACHC $23.83
- LEGN $30.25
- Resistance Level
- ACHC $28.48
- LEGN $33.30
- Average True Range (ATR)
- ACHC 1.34
- LEGN 1.78
- MACD
- ACHC 0.66
- LEGN -0.53
- Stochastic Oscillator
- ACHC 60.45
- LEGN 3.10
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.